Merck's COVID-19 pill active against Omicron in lab studies

1 minute read

An experimental COVID-19 treatment pill, called molnupiravir and being developed by Merck & Co Inc and Ridgeback Biotherapeutics LP, is seen in this undated handout photo released by Merck & Co Inc and obtained by Reuters May 17, 2021. Merck & Co Inc/Handout via REUTERS

Register now for FREE unlimited access to Reuters.com

Jan 28 (Reuters) - Merck & Co Inc (MRK.N) and partner Ridgeback Biotherapeutics said on Friday six lab studies showed their experimental oral COVID-19 drug molnupiravir was active against the fast-spreading Omicron variant.

The data evaluated the antiviral activity of molnupiravir and other COVID-19 antiviral agents against COVID-19 variants of concern. Molnupiravir is yet to be studied against Omicron in human studies, the companies said.

Molnupiravir and a rival oral pill from Pfizer Inc (PFE.N) were authorized in the United States in December and are considered as important tools against Omicron.

Register now for FREE unlimited access to Reuters.com

Pfizer said in December lab data suggested its drug Paxlovid retained its effectiveness against Omicron.

Merck said earlier this month its pill has a mechanism that can work against Omicron and any other variant.

Molnupiravir has been authorized for use in more than 10 countries, including the United States, United Kingdom and Japan.

Register now for FREE unlimited access to Reuters.com
Reporting by Manojna Maddipatla in Bengaluru; Editing by Shinjini Ganguli and Shounak Dasgupta

Our Standards: The Thomson Reuters Trust Principles.